Last reviewed · How we verify
2 - Insulin glargine QAM
At a glance
| Generic name | 2 - Insulin glargine QAM |
|---|---|
| Also known as | Trade name: Lantus |
| Sponsor | Charles Drew University of Medicine and Science |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians (PHASE4)
- A Study for Patients With Type 2 Diabetes (PHASE2)
- A Study for Patients With Type 1 Diabetes (PHASE2)
- Insulin Glargine at Bedtime or in AM Versus NPH (PHASE4)
- Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2 - Insulin glargine QAM CI brief — competitive landscape report
- 2 - Insulin glargine QAM updates RSS · CI watch RSS
- Charles Drew University of Medicine and Science portfolio CI